Inmune Bio (INMB) Other Non-Current Assets (2021 - 2026)
Inmune Bio (INMB) recorded Other Non-Current Assets of $537,000 in Q2 2026, down 5.8% from $570,000 a year earlier and down 21.4% from the prior quarter.
Powered by 
Analysis
Inmune Bio (INMB) Other Non-Current Assets (2021 - 2026) Analysis & Trends
At the end of FY2025, Inmune Bio reported Other Non-Current Assets of $595,000, up 653.2% from FY2024.
- Annual Other Non-Current Assets has a four-year compound annual growth rate of 56.6% (FY2021 to FY2025).
- Across earlier years, Other Non-Current Assets came in at $79,000 in FY2024 (-39.7%), $131,000 in FY2023 (+32.3%), $99,000 in FY2022 (unchanged) and $99,000 in FY2021.
- The Q2 2026 figure is the lowest quarterly Other Non-Current Assets since Q1 2025.
- On a year-over-year basis, Other Non-Current Assets rose in three of the last seven quarters, with growth averaging 275.8%.
- Peak year-over-year performance for Other Non-Current Assets in the last five years was growth of 809.8% in Q3 2025, against a decline of 53.8% in Q1 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $683,000 (Q1 2026), $595,000 (Q4 2025) and $746,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 7.48 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 14.27 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 10.73 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 19.60 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 5.93 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | - |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 12.98 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 4.75 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 9.94 Bn |
| 10 | Inmune Bio | 42.88 Mn | -49.37 Mn | - | 537,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 537,000.00 |
| Mar 31, 2026 | 683,000.00 |
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | 746,000.00 |
| Jun 30, 2025 | 570,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Mar 31, 2024 | 106,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 129,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 99,000.00 |
| Dec 31, 2022 | 99,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 99,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 99,000.00 |
| Sep 30, 2021 | 99,000.00 |
API Access
Inmune Bio Other Non-Current Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-non-current-assets&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-non-current-assets", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-non-current-assets&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();